Jagsonpal Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceutical Outlines Growth Strategy for Next Two Years in Concall Guidance Jan 23, 2026

Jagsonpal Pharmaceutical has provided strategic guidance for the next one to two years, expecting 50% of growth from price increases and new product/SKU introductions, with the remaining 50% from volume growth. The company anticipates increasing contributions from volume growth and new products over this period, reflecting a balanced approach to expansion through pricing strategies, product innovation, and market penetration.

Jagsonpal Pharmaceuticals Makes Q3 FY26 Earnings Call Audio Recording Available Jan 22, 2026

Jagsonpal Pharmaceuticals Schedules Q3FY26 Earnings Conference Call for January 22, 2026 Jan 15, 2026

Jagsonpal Pharmaceuticals Allots 1,09,180 Equity Shares Under ESOP 2022, Increases Paid-Up Capital Jan 06, 2026

Jagsonpal Pharmaceuticals Receives ₹1.52 Crore GST Demand Order from Haryana Tax Authorities Dec 30, 2025

More news about Jagsonpal Pharmaceuticals

18Nov 25

Jagsonpal Pharmaceuticals Boosts Employee Ownership with 56,571 Equity Shares Allotment

Jagsonpal Pharmaceuticals Limited has allotted 56,571 equity shares under its Employee Stock Option Plan 2022 (JPL ESOP 2022) on November 18, 2025. The allotment increased the company's paid-up share capital from Rs. 13,34,49,398 to Rs. 13,35,62,540, and total issued shares from 6,67,24,699 to 6,67,81,270. Shares were issued at different exercise prices: 46,246 at Rs. 94.00, 9,125 at Rs. 113.60, and 1,200 at Rs. 115.60. This move aims to enhance employee engagement, serve as a retention tool, and align employee interests with the company's long-term success.

07Nov 25

Jagsonpal Pharmaceuticals Reports Flat Q2 Growth, Appoints New COO and CFO

Jagsonpal Pharmaceuticals Limited reported flat Q2 revenue at Rs. 74.5 crores, maintaining EBITDA at Rs. 18.1 crores with a 24.3% margin. PAT grew by 10% to Rs. 12.6 crores. H1 performance showed 10% revenue growth to Rs. 150 crores and 39% PAT growth to Rs. 23.40 crores. The company appointed Amrut Medhekar as COO and Nirav Vora as CFO. Despite GST transition challenges, Jagsonpal maintained a strong cash position of Rs. 160.4 crores. Management expects low double-digit growth in H2, focusing on market penetration, core therapy expansion, and innovation.

03Nov 25

Jagsonpal Pharmaceuticals Reports Quarterly Results for Period Ended September 30, 2025

Jagsonpal Pharmaceuticals Limited announced its Q2 FY2025-26 results, showing a 9.73% increase in net profit to 125.74 million rupees, despite a 0.30% decrease in revenue to 744.65 million rupees. EBITDA improved to 165.00 million rupees, with the EBITDA margin expanding by 46 basis points to 22.15%. The company granted 272,500 stock options and allotted 104,774 equity shares under its ESOP. A final dividend of Rs. 2.5 per share for FY2024-25 was paid, totaling Rs. 166.58 million.

04Sept 25

Jagsonpal Pharmaceuticals Appoints Amrut Medhekar as Chief Operating Officer

Jagsonpal Pharmaceuticals Limited has appointed Mr. Amrut Medhekar as its new Chief Operating Officer (COO), effective September 04, 2025. Mr. Medhekar brings over 28 years of experience in the pharmaceutical sector, with expertise in Sales, Marketing, and Business Operations. He has previously held senior positions at companies like Akums Drugs & Pharmaceuticals, Torrent Pharmaceuticals, and Ranbaxy. The appointment, approved by the Board of Directors, aims to strengthen the company's operational capabilities and drive future growth.

31Jul 25

Jagsonpal Pharmaceuticals Reports Robust Q1FY26 Performance with 23% Revenue Growth and Doubled PAT

Jagsonpal Pharmaceuticals announced robust Q1FY26 results, with revenue growing 23% YoY to ₹75.50 crore and PAT doubling to ₹10.80 crore. Net margins improved by 560 bps to 14.30%, while operating EBITDA grew 24% to ₹15.70 crore. The company improved its Gynae CVM ranking to No. 7 and maintains top 5 positions in 14 of its top 15 brands. The Yash Pharma acquisition contributed ₹12.00 crore to the topline. Jagsonpal maintains a 15% growth guidance for FY26 with expected EBITDA margin expansion of 100-150 basis points. The company terminated CFO Sachin Jain's employment due to misconduct and misrepresentation.

28Jul 25

Jagsonpal Pharmaceuticals Doubles Q1 Net Profit, Reports Strong Revenue Growth

Jagsonpal Pharmaceuticals Ltd announced impressive Q1 financial results. Net profit reached ₹107.00 crore, a 101.89% increase year-over-year and 64.62% increase quarter-over-quarter. Revenue grew to ₹756.00 crore, up 23.13% year-over-year and 29.23% from the previous quarter. The results demonstrate significant growth in both revenue and profitability, indicating improved operational efficiency and strong market performance in the pharmaceutical sector.

07May 25

Jagsonpal Pharma Reports Q4 Profit Surge, Declares Dividend, and Terminates Business Transfer Agreement

Jagsonpal Pharmaceuticals Limited reported a significant increase in Q4 net profit, rising 85.9% year-on-year to ₹66.00 million. Revenue also grew by 34.7% to ₹586.00 million. The company declared a dividend of ₹2.50 per equity share. However, Q4 profit decreased from ₹320.00 million in the previous quarter. Jagsonpal also announced the termination of a business transfer agreement for the acquisition of Resilient due to unmet conditions.

06May 25

Jagsonpal Pharma Cancels Acquisition of Resilient as Business Transfer Agreement Terminated

Jagsonpal Pharmaceuticals Limited has announced the termination of its business transfer agreement for the acquisition of Resilient. The decision was reached mutually between Jagsonpal Pharma and the seller due to unfulfilled conditions precedent. This development marks a significant change in Jagsonpal Pharma's strategic plans, potentially affecting its expansion strategy. The company will need to reassess its growth plans in light of this cancellation.

06May 25

Jagsonpal Pharma Declares Dividend Amidst Impressive Q4 Results

Jagsonpal Pharmaceuticals Limited has reported impressive Q4 financial results. Revenue increased by 34.74% to ₹586.00 crore, while net profit surged by 85.92% to ₹66.00 crore. EBITDA showed a remarkable growth of 225.96%, reaching ₹87.00 crore. The company's EBITDA margin expanded to 14.85% from 6.14%. Additionally, Jagsonpal Pharma announced a dividend of ₹2.50 per equity share.

02Apr 25

Jagsonpal Pharma Faces ₹10.19 Crore Customs Duty Demand and Penalty

Jagsonpal Pharmaceuticals has received a customs order confirming a differential duty of ₹5.09 crore and an equivalent penalty, totaling ₹10.19 crore. The demand stems from an alleged incorrect classification of imported goods. The company maintains it has followed the correct classification and plans to file an appeal, believing it has merits in the case and does not expect any material financial impact.

21Feb 25

Jagsonpal Pharmaceuticals Expands Portfolio with ₹24 Crore Acquisition of Resilient Cosmeceuticals' India Business

Jagsonpal Pharmaceuticals has signed a Business Transfer Agreement to acquire Resilient Cosmeceuticals' India business for ₹24 crore. The deal, expected to close within 45 days, will be funded through internal accruals. This acquisition expands Jagsonpal's portfolio in Pharmaceuticals, Nutritional, and Cosmetic products, strengthening its position in Gynaecology and Dermatology. The move is set to enhance Jagsonpal's market presence, particularly in Maharashtra, Karnataka, and Kerala, and is projected to improve its market ranking from 75th to 71st in the pharmaceutical sector.

21Feb 25

Jagsonpal Pharmaceuticals Faces FDA Warning: Potential Impact on US Sales

Jagsonpal Pharmaceuticals has received a warning letter from the U.S. FDA dated February 5, 2025, citing CGMP violations and registration issues at a contract manufacturing facility. The company disclosed potential sales loss of 35 million INR (1.46% of annual sales) due to this warning. Jagsonpal currently supplies only one OTC API to the U.S. market. The company informed stock exchanges on February 21, 2025, in compliance with SEBI regulations.